Pharmicell Cash Flow Conversion Efficiency

Latest as of September 2025: 0.080x

Pharmicell cash flow conversion efficiency. Based on the latest financial reports, Pharmicell (005690) has a cash flow conversion efficiency ratio of 0.080x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩8.78 Billion ≈ $5.95 Million USD) by net assets (₩110.43 Billion ≈ $74.83 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Cash Flow Conversion Efficiency of Pharmicell (2010–2024)

Cash flow conversion efficiency of Pharmicell from 2010 to 2024. This chart illustrates how Pharmicell's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Pharmicell stock quote for real-time trading data and today's change.

Pharmicell Cash Flow Conversion Ratio Explained

Pharmicell cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.

Pharmicell Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Pharmicell ranked by their cash flow conversion efficiency. Also see Pharmicell market capitalisation for the company's overall valuation and market capitalisation.

Company	Cash Flow Conversion Efficiency
Tsogo Sun JSE:TSG	0.196x
Checkpoint Therapeutics Inc NASDAQ:CKPT	-0.717x
Van de Velde NV BR:VAN	0.127x
mF International Limited Ordinary Shares NASDAQ:MFI	-0.118x
Shen Zhen Australis Electronic Technology Co.Ltd. SHE:300940	0.035x
BETTER COLLECTIVE EO-01 F:9C8	0.026x
Brunel International NV AS:BRNL	-0.021x
Funko Inc NASDAQ:FNKO	0.072x

Annual Cash Flow Conversion Efficiency for Pharmicell (2010–2024)

The table below shows the annual cash flow conversion efficiency of Pharmicell from 2010 to 2024. Review Pharmicell (005690) free cash flow to assess how much free cash flow the company generates relative to operating cash flow.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	₩86.44 Billion ≈ $58.58 Million	₩3.50 Billion ≈ $2.37 Million	0.040x	-72.46%
2023-12-31	₩80.40 Billion ≈ $54.48 Million	₩11.81 Billion ≈ $8.01 Million	0.147x	+42.35%
2022-12-31	₩76.66 Billion ≈ $51.95 Million	₩7.91 Billion ≈ $5.36 Million	0.103x	+226.26%
2021-12-31	₩63.87 Billion ≈ $43.28 Million	₩-5.22 Billion ≈ $-3.54 Million	-0.082x	-152.00%
2020-12-31	₩57.11 Billion ≈ $38.70 Million	₩8.98 Billion ≈ $6.08 Million	0.157x	+10828.39%
2019-12-31	₩51.52 Billion ≈ $34.91 Million	₩-75.50 Million ≈ $-51.16K	-0.001x	-102.04%
2018-12-31	₩47.49 Billion ≈ $32.18 Million	₩3.40 Billion ≈ $2.31 Million	0.072x	+300.00%
2017-12-31	₩55.99 Billion ≈ $37.95 Million	₩-2.01 Billion ≈ $-1.36 Million	-0.036x	-442.90%
2016-12-31	₩94.60 Billion ≈ $64.11 Million	₩988.97 Million ≈ $670.21K	0.010x	+132.06%
2013-12-31	₩82.42 Billion ≈ $55.86 Million	₩-2.69 Billion ≈ $-1.82 Million	-0.033x	+72.09%
2012-12-31	₩101.58 Billion ≈ $68.84 Million	₩-11.87 Billion ≈ $-8.04 Million	-0.117x	+40.15%
2011-12-31	₩82.82 Billion ≈ $56.13 Million	₩-16.17 Billion ≈ $-10.96 Million	-0.195x	+77.02%
2010-12-31	₩9.90 Billion ≈ $6.71 Million	₩-8.41 Billion ≈ $-5.70 Million	-0.850x	--

About Pharmicell

KO:005690 Korea Biotechnology

Market Cap

$367.60 Million

₩542.44 Billion KRW

Market Cap Rank

#13580 Global

#397 in Korea

Share Price

₩9040.00

Change (1 day)

+1.57%

52-Week Range

₩8760.00 - ₩20250.00

All Time High

₩25150.00